AMRA
AMRA has announced at the European Congress of Radiology in Vienna, Austria, that it has entered into a new co-marketing agreement with GE Healthcare, a leading provider of MRI systems. This agreement confirms that AMRATM Profiler protocol will be made available on future GE Healthcare MRI scanners.
AMRATM Profiler is a cloud-based body composition measurement service, which uses images from a rapid, 6-minute MRI scan to deliver accurate, precise fat and muscle measurements.2 As the world’s first CE approved* technology of its kind, AMRATM Profiler introduces new standards in body composition measurement and imaging biomarkers.
“This co-marketing agreement marks an important milestone in our relationship with AMRA and we are proud to be able deliver access to AMRA cloud based body composition analysis to GE customers,” said Mark Stoesz, Global Product Marketing Manager at GE Healthcare. “In light of GE Healthcare’s strong heritage in MRI technology, this collaboration is a welcome opportunity to combine our expertise and deliver new value to physicians and their patients.”
Medical assessments of body composition have traditionally relied upon BMI and waist circumference; indirect measurements that do not distinguish between different parts of the body and give little information about metabolic status. The location and distribution of different types of fat can affect an individual’s likelihood of developing metabolic-related diseases.3,4 Gaining precise measurements of an individual's various fat and muscle volumes can therefore provide a more accurate assessment of a person’s health status. Through international collaboration with world-leading researchers, AMRA is also building upon its precise measurement technology to develop the Body Composition Profile (BCP), a complementary tool that can be used alongside BMI to deliver a clearer picture of an individual’s health and metabolic risk.
“Over 2.1 billion people in the world are characterised as overweight or obese,5 placing a major and growing burden on global health systems,” said Tommy Johansson, CEO of AMRA.
“AMRA aims to assist the world’s medical leaders in providing better body composition measurements, leading to more personalised treatment for people at risk of poor metabolic health outcomes. The AMRA and GE Healthcare co-marketing agreement is a significant step forward in this ambition.”
The co-marketing agreement follows two recent AMRA milestones, including CE Mark approval for the clinical use of AMRATM Profiler in January 2016, allowing European clinicians to use AMRATM Profiler measurements in patient care. Additionally, in 2015 AMRA announced the company has entered into a unique international collaboration with Pfizer Inc. to investigate the relationship between fat and muscle distribution in the body and metabolic health, including risk factors for conditions such as obesity and diabetes.
For further information regarding AMRA please visit: www.amra.se
*A mandatory conformity marking for certain products sold within the European Economic Area
-ENDS-
About AMRA
AMRA is an international medical technology company and the first in the world to transform MR images into precise body composition measurements using a cloud-based, computer-aided service.
AMRA collaborates with world-leading pharmaceutical organisations, biobanks and population cohorts, research institutions, hospitals, and clinics, aiding in the advancement of metabolic research and therapeutic application. By offering access to more accurate knowledge about our bodies, AMRA can assist the world's medical leaders in predicting and preventing disease.
Headquartered in Sweden, AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden.
References
1 Information on file. AMRA March 2016
2 Magnus Borga, et al. NMR in Biomedicine, Volume 28, Issue 12, p1747–1753, December 2015
3 Jean-Pierre Després et al. Nature 444, 881-887 (14 December 2006)
4 Ian J. Neeland, MD et al. J Am Coll Cardiol. 2015;65(19):2150-2151
5 Marie Ng, PhD et al. The Lancet, Volume 384, No. 9945, p766–781, 30 August 2014
View source version on businesswire.com: http://www.businesswire.com/news/home/20160303005136/en/
Contact:
GCI Health
Charlotte Collins
Tel: +44(0)207-072-4214
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Completes Divestiture of Pharma Solutions Business Unit1.5.2025 08:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its Pharma Solutions business unit to Roquette. “The completion of our Pharma Solutions divestiture represents a significant milestone for IFF as we delivered our targeted net debt to credit-adjusted EBITDA of below 3.0x,” said Erik Fyrwald, IFF CEO. “This is an important step as it allows us to focus on our core strategy – capitalizing on the exciting growth opportunities within our key businesses – as we maximize long-term value for our shareholders. We’d like to thank our Pharma Solutions colleagues for their unwavering commitment and their dedication to exceptional customer service. We wish them continued success as they find a new home with Roquette.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that
More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 20251.5.2025 08:00:00 CEST | Press release
Varian, a Siemens Healthineers company, will showcase an integrated portfolio designed to streamline workflows, and aiming to enhance patient experience and improve patient outcomes from screening to survivorship at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 2-6, in Vienna, Austria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430039992/en/ At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our pers
REI Super Selects SS&C For Superannuation Administration1.5.2025 05:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W
Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 03:25:00 CEST | Press release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi
Andersen Global udvider sin europæiske værdiansættelseskapacitet gennem samarbejde med Value & Risk Valuation Services1.5.2025 03:03:00 CEST | Pressemeddelelse
Andersen Global fortsætter med at styrke sin værdiansættelseskapacitet gennem en samarbejdsaftale med Value & Risk Valuation Services, et fremtrædende europæisk værdiansættelsesfirma med hovedsæde i Tyskland og kontorer i Luxembourg og Østrig. Value & Risk Valuation Services blev grundlagt i 1996 og er et ledelsesejet firma, der har specialiseret sig i værdiansættelse af finansielle aktiver på tværs af forskellige aktivklasser og med varierende kompleksitet. Firmaet leverer også supplerende tjenester, herunder uafhængig prisverifikation (IPV), risikoanalyse og analyse af transaktionsomkostninger. Siden 2009 har virksomheden været ledet af Gil Bender, som er dedikeret til at levere kundecentrerede værdiansættelsesløsninger af høj kvalitet. Som en af de få europæiske udbydere, der tilbyder eksterne værdiansættelsestjenester i overensstemmelse med det europæiske direktiv om forvaltere af alternative investeringsfonde (AIFMD), opretholder Value & Risk de højeste industristandarder for over
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom